Forget Biogen: These 2 Alzheimer's Drug Stocks Could Make You Rich

The decision by the FDA to approve Biogen's (NASDAQ: BIIB) Alzheimer's disease treatment aducanumab, to be marketed as Aduhelm, has given new hope to more than 5 million Americans with the disease, and their loved ones. When the Food and Drug Administration initially signaled in November that it was likely to approve the monoclonal antibody treatment, Biogen stock jumped by 43%, adding $16 billion in market capitalization to the company.

Unfortunately, the questions surrounding the treatment and its efficacy may leave many doctors hesitant to recommend it. Add in the expected $50,000 annual price tag and the case for Aduhelm gets even harder to make. For investors, that could prove an incentive to go looking for companies that might provide more promising Alzheimer's disease treatments.

Cassava Sciences (NASDAQ: SAVA) and Annovis Bio (NYSEMKT: ANVS) have arguably better prospects in their pipelines, and almost certainly more upside should their therapies get approved. Although small biotech stocks are risky, these two companies could turn out to be life-changing investments for some, if their potentially life-changing treatments prove effective.

Continue reading

Source Fool.com